Exabis Library
Welcome to the e-CCO Library!
DOP014: Impact of genetic variation on gene and protein expression in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP014: Nutritional optimisation of presurgical Crohn’s disease patients with enteral nutrition significantly decreases length of stay and need for a stoma
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP014: Transmural healing is better than mucosal healing in Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP015: Dysregulation of cell-type-specific long ncRNA in the ileum of treatment naïve early onset Crohn disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP015: International differences in gastroenterologists' perspective on stopping therapy for patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP015: Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP016: Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP016: Postoperative clinical recurrence is not different in Crohn’s disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neoterminal ileum
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP017: Colectomy-free survival is independent of initial infliximab dosing strategy in hospitalised ulcerative colitis patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP017: Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP018: Effect of adalimumab on extraintestinal manifestations among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP018: Long-term follow-up after ileorectal anastomosis in ulcerative colitis (UC) identified factors associated with rectal outcome: a multicentre retrospective cohort of 343 patients from the GETAID/GETAID Surgery
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP019: Effect of vedolizumab treatment on extraintestinal manifestations in patients with Crohn's disease: a GEMINI 2 post hoc analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP019: Efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP019: Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP01: A multi-centre study to explore the prevalence of Inflammatory Bowel Disease indicators in patients with moderate- to- severe psoriasis: Baseline results from the EPIC study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
Friday, 4 March 2022, 1:45 PM by Dietrich Diz Angerer-GTN
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM